Financials data is unavailable for this security.
View more
Year on year Shanghai Henlius Biotech Inc grew revenues 67.82% from 3.21bn to 5.39bn while net income improved from a loss of 695.26m to a gain of 546.02m.
Gross margin | 73.23% |
---|---|
Net profit margin | 12.27% |
Operating margin | 14.90% |
Return on assets | 7.07% |
---|---|
Return on equity | 30.99% |
Return on investment | 14.25% |
More ▼
Cash flow in CNYView more
In 2023, Shanghai Henlius Biotech Inc increased its cash reserves by 28.83%, or 194.19m. The company earned 1.05bn from its operations for a Cash Flow Margin of 19.42%. In addition the company generated 144.43m cash from financing while 1.00bn was spent on investing.
Cash flow per share | 2.09 |
---|---|
Price/Cash flow per share | 9.96 |
Book value per share | 5.10 |
---|---|
Tangible book value per share | -4.43 |
More ▼
Balance sheet in CNYView more
Current ratio | 0.4888 |
---|---|
Quick ratio | 0.329 |
Total debt/total equity | 1.57 |
---|---|
Total debt/total capital | 0.6113 |
More ▼